

Elekta and software partner AnSheng enter joint venture to strengthen market position in China

STOCKHOLM – Elekta (EKTA-B.ST) announces that it has entered into a joint venture with AnSheng, its Chinese software partner. This strategic investment aims to ensure Elekta's market-leading position in China and accelerate the adoption of radiation therapy in the country.

By investing in AnSheng, Elekta will drive product improvements, ensuring a better customer experience, while strengthening Elekta's position in vendor-agnostic oncology information systems tailored to the needs of the Chinese market. These advancements will aim to improve clinical operations at cancer centers by elevating the overall quality and efficiency of radiotherapy solutions offered to Elekta customers in the country.

Anming Gong, Executive Vice President for Region China, says: "This investment marks a significant milestone in our commitment to the Chinese market. By partnering more closely with AnSheng, we can enhance our software product offerings and better serve customers, ultimately improving patient outcomes. In addition, this further supports our position as the leading solution provider in China, and we are excited about the opportunities the collaboration will bring."

Maurits Wolleswinkel, President Linac & Software Solutions, adds: "Through this joint venture we are adding a localized solution to our evolving Elekta ONE software ecosystem. I look forward to working more closely with AnSheng on streamlined and efficient patient care as we accelerate our joint roadmap and offering."

The joint venture governance ensures Elekta's continued access to AnSheng's vital software solutions, enabling better alignment of the product and commercial strategy to maximize impact.

#

For further information, please contact:

Mattias Thorsson, Vice President, Head of Corporate Communications

Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com

Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations

Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com

Time zone: ET: Eastern Time

About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm,



Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit [elekta.com](https://www.elekta.com) or follow [@Elekta](https://twitter.com/Elekta) on “X”, formerly known as Twitter.